STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Sep. 30, 2018	28,034,487
Beginning balance, amount at Sep. 30, 2018	$ 280,346	$ 331,312,184	$ (331,591,614)	$ 916
Warrant exercises, shares	298,682
Warrant exercises	$ 2,987	646,766		649,753
Equity based compensation - employees		573,660		573,660
401(k) contributions paid in common stock, shares	12,279
401(k) contributions paid in common stock	$ 123	35,118		35,241
Stock issued to nonemployees for service, shares	62,784
Stock issued to nonemployees for service	$ 628	201,752		202,380
Shares issued (returned) for settlement of clinical research costs, shares	(564,905)
Shares issued (returned) for settlement of clinical research costs	$ (5,649)	5,649		0
Net income (loss)			1,245,902	1,245,902
Ending balance, shares at Dec. 31, 2018	27,843,327
Ending balance, amount at Dec. 31, 2018	$ 278,435	332,775,129	(330,345,712)	2,707,852
Beginning balance, shares at Sep. 30, 2019	35,231,776
Beginning balance, amount at Sep. 30, 2019	$ 352,318	358,507,603	(353,726,254)	5,133,667
Adoption of new accounting standard - RESTATED			2,146,195	2,146,195
Issuance of common stock, shares	606,395
Issuance of common stock, amount	$ 6,064	5,043,939		5,050,003
Warrant exercises, shares	132,900
Warrant exercises	$ 1,329	295,772		297,101
Equity based compensation - employees		1,800,225		1,800,225
401(k) contributions paid in common stock, shares	4,474
401(k) contributions paid in common stock	$ 45	40,892		40,937
Stock issued to nonemployees for service, shares	15,819
Stock issued to nonemployees for service	$ 158	84,289		84,447
Purchase of stock by officers and directors, shares	3,725
Purchase of stock by officers and directors	$ 37	24,963		25,000
Stock issuance cost		(92,150)		(92,150)
Net income (loss)			(5,531,360)	(5,531,360)
Ending balance, shares at Dec. 31, 2019	35,995,089
Ending balance, amount at Dec. 31, 2019	$ 359,951	$ 365,705,533	$ (357,111,419)	$ 8,954,065